CCCA Hair Loss: What to Know and How to Track

Central centrifugal cicatricial alopecia (CCCA) is the most common form of scarring hair loss in Black women. Olsen et al. published in the Journal of the American Academy of Dermatology (2011) that CCCA affects up to 5.6% of Black women in the United States. Despite that prevalence, CCCA remains dramatically underdiagnosed and underrepresented in hair loss content, clinical education, and public awareness. Most hair loss articles focus on androgenetic alopecia or telogen effluvium. CCCA is a different condition entirely. It is a scarring alopecia, meaning it destroys hair follicles permanently. Once a follicle is scarred, no treatment can bring it back. That single fact makes early detection the most important factor in CCCA outcomes, and it makes photo tracking of the crown area not just useful but essential.

Start tracking your crown before scarring spreads

HairLossTracker helps you photograph your crown at consistent angles every month, document scalp changes, and build the visual timeline your dermatologist needs to see whether treatment is working.

Use the BaldingAI hair tracking app to save one baseline session now, compare monthly checkpoints later, and keep one clear record for your next treatment or dermatologist decision.

Start Tracking In BaldingAITry free tools or compare the app first

What is CCCA?

CCCA is a chronic inflammatory condition that targets hair follicles, starting at or near the crown (vertex) of the scalp and spreading outward in a centrifugal pattern. The name describes the progression: central (starts at the center/crown), centrifugal (spreads outward), cicatricial (scarring), alopecia (hair loss). The inflammation is lymphocytic, meaning lymphocytes infiltrate the area around hair follicles and gradually destroy the follicular structures. As the follicles are destroyed, they are replaced by fibrous scar tissue. The overlying scalp may appear smooth, shiny, or slightly discolored compared to surrounding skin.

CCCA progresses slowly in most cases. Many women first notice gradual thinning at the crown that they attribute to normal aging or stress. The condition can be active for years before receiving a correct diagnosis. By that point, significant follicular destruction may have already occurred. This slow, insidious progression is one of the reasons CCCA is so often diagnosed late.

Who does CCCA affect?

CCCA predominantly affects women of African descent. Studies consistently show the highest prevalence in Black women, with onset typically between ages 30 and 55. While the condition can occur in other populations, it is rare outside of African-descent communities. Men of African descent can also develop CCCA, though it is far less common and often misdiagnosed as standard androgenetic alopecia.

The demographic specificity of CCCA has contributed to its historical neglect in both research and clinical training. Dermatology training programs have historically underrepresented conditions affecting skin and hair of color. This means many general dermatologists may not recognize early CCCA, particularly when it resembles early-stage female pattern hair loss at initial presentation. Seeking a dermatologist experienced with hair loss in skin of color, or a trichologist, significantly improves the chance of early and accurate diagnosis.

The PADI3 genetic discovery

In 2019, Malki et al. published a landmark study in the New England Journal of Medicine identifying a variant in the PADI3 gene strongly associated with CCCA. The PADI3 gene encodes an enzyme (peptidylarginine deiminase type III) involved in the structural formation of the inner root sheath of the hair follicle. When this enzyme is disrupted, the inner root sheath does not form properly, leading to hair shaft fragility and premature follicular breakdown.

This discovery was significant for several reasons. First, it established that CCCA has a clear genetic component, challenging the earlier assumption that hair care practices were the primary cause. Second, it provided a biological mechanism explaining why certain follicles become vulnerable to the inflammatory attack that characterizes CCCA. Third, it opened the door for potential genetic testing and future targeted therapies. The PADI3 variant is not present in all CCCA patients, suggesting that other genetic factors likely contribute, but the finding shifted the understanding of CCCA from a purely environmentally-triggered condition to one with strong genetic underpinnings.

Risk factors: genetics and hair care practices

The relationship between hair care practices and CCCA is nuanced and has evolved significantly in recent years. Earlier literature emphasized chemical relaxers, tight braiding, sew-in weaves, and high-heat styling as primary drivers of CCCA. Current understanding recognizes these practices as potential aggravating factors in genetically susceptible individuals rather than standalone causes.

Chemical relaxers are the most studied external risk factor. Kyei et al. (2011, Archives of Dermatology) found that early and frequent use of chemical relaxers was associated with higher CCCA prevalence. Traction from tight hairstyles can compound damage in areas already affected by CCCA-related inflammation. Heat styling above 230 degrees Celsius directly damages the hair cuticle and may worsen breakage in follicles already compromised by the PADI3-related structural defect.

The critical point: not every woman who uses chemical relaxers or tight styles develops CCCA, and some women with CCCA have never used these practices. The genetic component is real and substantial. Blaming hair care choices alone is both scientifically incomplete and potentially harmful because it can delay diagnosis while women change styling habits and wait for improvement that will not come without medical treatment.

Early signs to watch for

CCCA announces itself subtly. The earliest signs are easy to dismiss, which is exactly why active monitoring matters.

• Central vertex thinning. Gradual widening of the part or visible scalp at the crown. This is often the first noticeable change and the most frequently misattributed to normal aging.
• Scalp tenderness or itching at the crown. A burning or tingling sensation at the crown, particularly if it persists, can indicate active inflammation beneath the surface.
• Shiny, smooth scalp patches. As follicles are destroyed and replaced by scar tissue, the affected skin appears smoother and shinier than surrounding areas.
• Breakage concentrated at the crown. Short, broken hairs near the vertex that do not correspond to mechanical damage from styling.
• Loss of follicular ostia. When you look closely at the affected area, the tiny pores where hairs emerge may be absent. Normal scalp shows visible follicular openings; scarred scalp does not.

If you notice any combination of these signs, do not wait. CCCA does not reverse on its own, and every month of uncontrolled inflammation means more permanent follicular destruction. For a broader guide on when scalp biopsy is appropriate, see our scalp biopsy guide.

Diagnosis: why scalp biopsy is essential

CCCA cannot be definitively diagnosed by visual inspection alone. The clinical appearance, particularly in early stages, overlaps with female pattern hair loss (androgenetic alopecia) and other forms of scarring alopecia like lichen planopilaris. A scalp biopsy is the gold standard diagnostic tool. The biopsy reveals the specific pattern of lymphocytic inflammation around hair follicles, premature desquamation of the inner root sheath, and fibrosis (scarring) replacing destroyed follicular structures.

The biopsy is a 4mm punch procedure performed under local anesthetic. It takes 5 to 10 minutes, requires one to two stitches, and heals within 7 to 14 days. The sample is sent to a dermatopathologist who examines it under a microscope. Results typically return within 1 to 2 weeks. A dermoscopy exam (magnified scalp examination) can support the clinical suspicion, but the biopsy provides definitive confirmation.

Getting the biopsy is non-negotiable if CCCA is suspected. The treatment approaches for CCCA differ substantially from those for androgenetic alopecia. Treating suspected CCCA as pattern hair loss wastes critical time while scarring progresses. If your dermatologist does not suggest a biopsy when you present with central vertex thinning and scalp symptoms, ask for one directly.

Treatment options

CCCA treatment focuses on two goals: stopping the inflammatory destruction of remaining follicles and, where possible, stimulating regrowth from follicles that have not yet been permanently scarred. No single treatment works for everyone, and most dermatologists use a combination approach.

Topical corticosteroids (clobetasol propionate 0.05%) applied to the affected area reduce surface inflammation. These are often the first-line treatment, applied daily or every other day for 2 to 4 weeks, then tapered to maintenance frequency. They are most effective for mild, early-stage CCCA.

Intralesional corticosteroid injections (triamcinolone acetonide, typically 5 to 10 mg/mL) deliver anti-inflammatory medication directly into the affected scalp tissue. Injections are administered every 4 to 6 weeks and are considered more effective than topical steroids for moderate CCCA because they reach deeper into the follicular inflammation.

Doxycycline at sub-antimicrobial doses (40 to 100 mg daily) is used for its anti-inflammatory properties rather than its antibiotic function. It can be taken long-term and is often combined with topical treatments. Some dermatologists use minocycline as an alternative.

Hydroxychloroquine (200 to 400 mg daily) is a systemic anti-inflammatory used for more aggressive or widespread CCCA. It requires baseline and annual eye exams because of a rare but real risk of retinal toxicity with long-term use. Response typically takes 3 to 6 months to assess.

Topical minoxidil (5%) can help stimulate growth from follicles that are not yet scarred. It does not address the underlying inflammation but can improve density in areas where viable follicles remain. It is almost always used alongside anti-inflammatory treatments, never as a standalone CCCA therapy.

Distinguishing CCCA from androgenetic alopecia

Both CCCA and female pattern hair loss (AGA) can present as central vertex thinning. The overlap in location causes frequent misdiagnosis. Several features help distinguish them. CCCA typically causes scalp symptoms (tenderness, itching, burning) while AGA is usually asymptomatic. CCCA produces smooth, shiny patches where follicular openings are absent; AGA retains visible follicular ostia even in thinned areas. CCCA progression is centrifugal (spreading outward from the crown); AGA follows a more diffuse thinning pattern across the top of the scalp. For more on distinguishing hair loss types, see our guide on frontal fibrosing alopecia, another scarring condition with distinct features.

The most reliable distinguishing factor remains the scalp biopsy. If there is any question about whether crown thinning represents CCCA or AGA, biopsy resolves it. Treating AGA when the actual condition is CCCA means the scarring continues unchecked.

How to track CCCA: a crown-focused protocol

Tracking CCCA serves a specific clinical purpose: determining whether treatment is halting the centrifugal spread of scarring. Your photo protocol should focus on the crown and document changes every 4 weeks. Use our crown thinning tracking guide to structure your approach.

• Overhead crown photo. Part your hair naturally and photograph directly down at the crown from a fixed distance (12 to 18 inches). Same lighting, same angle, every session.
• 4-quadrant documentation. Divide the crown area into front, back, left, and right quadrants. Note which quadrants show active thinning versus stable areas.
• Scalp surface notes. Document any shiny patches, visible scarring, absent follicular openings, or areas of tenderness. These clinical signs help your dermatologist assess inflammation activity.
• Symptom log. Record itching, tenderness, or burning episodes between appointments. Increased symptoms may indicate an active inflammatory flare requiring treatment adjustment.
• Treatment adherence log. Track daily topical application, injection dates, and oral medication compliance. Gaps in treatment compliance are the most common reason for perceived treatment failure.

The 3-month and 6-month comparison points are the most meaningful. At 3 months, you are primarily assessing whether the affected area has stopped expanding. At 6 months, you can evaluate whether any density improvement is occurring in areas where viable follicles remain. Bring your photo timeline to every dermatology appointment. Visual documentation over time is far more useful than a single clinical examination for tracking a condition that moves this slowly. For broader tracking fundamentals, explore our hair loss tracking blog.

Frequently asked questions

What causes CCCA?

CCCA results from a combination of genetic susceptibility and environmental factors. The PADI3 gene variant (Malki et al., 2019, NEJM) disrupts the inner root sheath of the hair follicle, making it vulnerable to inflammatory destruction. Chemical relaxers, tight hairstyles, and heat styling may aggravate the condition in genetically susceptible individuals, but they do not cause CCCA on their own.

Is CCCA reversible?

Follicles that have been completely destroyed by scarring cannot regrow hair. That damage is permanent. Follicles in the early stages of inflammation, before complete fibrosis, may recover with treatment. This is why early detection determines the outcome: the earlier treatment begins, the more follicles can be saved. Treatment can halt progression, and topical minoxidil may improve density in non-scarred areas.

How is CCCA diagnosed?

Definitive diagnosis requires a 4mm punch scalp biopsy examined by a dermatopathologist. The biopsy shows lymphocytic inflammation around follicles, premature desquamation of the inner root sheath, and fibrosis replacing destroyed follicles. Dermoscopy supports clinical suspicion but cannot confirm the diagnosis alone. Visual inspection is insufficient because early CCCA closely resembles female pattern hair loss.

What treatments work for CCCA?

First-line treatments include topical and intralesional corticosteroids to reduce inflammation. Doxycycline at anti-inflammatory doses and hydroxychloroquine are used for more extensive disease. Topical minoxidil (5%) helps stimulate growth from surviving follicles. Most dermatologists use a combination of anti-inflammatory and growth-stimulating treatments. Response is typically assessed at 3 to 6 months, and long-term maintenance therapy is often necessary to prevent recurrence.